Scarica l'app Stockscreener
3.47
0.58%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.45
Aprire:
$3.48
Volume 24 ore:
313.36K
Relative Volume:
0.51
Capitalizzazione di mercato:
$228.52M
Reddito:
-
Utile/perdita netta:
$-26.25M
Rapporto P/E:
-8.4655
EPS:
-0.4099
Flusso di cassa netto:
$-20.05M
1 W Prestazione:
-16.89%
1M Prestazione:
-11.48%
6M Prestazione:
+4.83%
1 anno Prestazione:
+18.03%
Intervallo 1D:
$3.33
$3.60
Intervallo di 1 settimana:
$3.33
$4.4573
Portata 52W:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Nome
Galectin Therapeutics Inc
Settore
Industria
Telefono
678-620-3186
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
3.47 | 228.52M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-13 | Iniziato | B. Riley FBR | Buy |
| 2017-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-19 | Iniziato | ROTH Capital | Buy |
| 2017-03-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Downgrade | ROTH Capital | Buy → Sell |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-09-21 | Iniziato | H.C. Wainwright | Buy |
| 2014-08-01 | Downgrade | Aegis Capital | Buy → Hold |
| 2014-07-30 | Reiterato | MLV & Co | Buy |
| 2014-07-29 | Reiterato | MLV & Co | Buy |
| 2014-04-02 | Reiterato | MLV & Co | Buy |
| 2014-02-10 | Reiterato | Aegis Capital | Buy |
| 2014-01-09 | Reiterato | Aegis Capital | Buy |
| 2013-12-03 | Iniziato | MLV & Co | Buy |
| 2013-08-19 | Reiterato | Aegis Capital | Buy |
Mostra tutto
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
Galectin Therapeutics (NASDAQ:GALT) Breaks a Key Trend Line - Kalkine Media
GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress - AD HOC NEWS
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat
GALT stock gains support as Galectin Therapeutics keeps cash focus - AD HOC NEWS
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Galectin Therapeutics CMO Jamil Khurram disposes of 16,250 common shares for $83,284.5 - Bitget
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
$Galectin Therapeutics (GALT.US)$ - Moomoo
$Galectin Therapeutics (GALT.US)$ put CMO at the table with who at solar? - Moomoo
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Galectin Therapeutics (GALT) Gains 4.16% as Biotech Momentum BuildsTriple Top - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com South Africa
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com
Galectin Therapeutics (GALT) Slips 1.8% as Stock Tests Key Support at $4.66Volume Oscillator - dars.gov.et
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000 Growth Benchmark - marketscreener.com
If you're not following me on stocktwits you probably should My money is on a partnership with Madrigal - Moomoo
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
GALTGalectin Therapeutics Inc Revenue Breakdown - Finviz
$Galectin Therapeutics (GALT.US)$ The FIB Strikes Again!! - Moomoo
Galectin Therapeutics Inc. Actuals & Estimates (FWB:PHPN) - TradingView
GALT Forecast — Price Target — Prediction for 2027 - TradingView
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram sells $23,728 in shares - Investing.com
Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Galectin Therapeutics Inc Azioni (GALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jamil Khurram | Chief Medical Officer |
Jul 14 '26 |
Sale |
5.13 |
16,250 |
83,284 |
0 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Option Exercise |
1.23 |
22,268 |
27,390 |
28,768 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Option Exercise |
1.23 |
7,732 |
9,510 |
14,232 |
| Shlevin Harold H. | Director |
Jun 29 '26 |
Sale |
5.04 |
22,268 |
112,231 |
6,500 |
| Shlevin Harold H. | Director |
Jun 26 '26 |
Sale |
5.00 |
7,732 |
38,660 |
6,500 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Option Exercise |
2.50 |
47,467 |
118,668 |
47,467 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Option Exercise |
2.37 |
4,570 |
10,814 |
2,533 |
| Jamil Khurram | Chief Medical Officer |
Jun 29 '26 |
Sale |
5.04 |
47,467 |
239,234 |
0 |
| Jamil Khurram | Chief Medical Officer |
Jun 26 '26 |
Sale |
5.00 |
4,570 |
22,850 |
0 |
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):